# Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

> **NCT05822544** · PHASE1 · RECRUITING · sponsor: **OrsoBio, Inc** · enrollment: 564 (estimated)

## Conditions studied

- Healthy Subjects
- Obesity
- Type 2 Diabetes

## Interventions

- **DRUG:** TLC-6740 Oral Solution
- **OTHER:** Placebo Oral Solution
- **DRUG:** TLC-6740 Tablet
- **DRUG:** Drug Metabolizing Enzyme
- **DRUG:** Tirzepatide
- **OTHER:** Placebo Tablet

## Key facts

- **NCT ID:** NCT05822544
- **Lead sponsor:** OrsoBio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-22
- **Primary completion:** 2026-02
- **Final completion:** 2026-06
- **Target enrollment:** 564 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822544, "Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05822544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*